Foghorn Therapeutics Inc. — Form 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Current Report on Form 8-K dated April 27, 2021. The filing concerns a corporate governance appointment and does not report quarterly or annual operating results.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- On April 27, 2021, the Board of Directors elected Ian F. Smith as a Class II director.
- Mr. Smith’s term expires at the 2022 annual meeting of stockholders.
- He will receive compensation under the company’s non-employee director compensation policy.
- He received an option to purchase 25,060 shares of common stock. The option vests in equal annual installments over three years, subject to continued service, with accelerated vesting upon a change of control before full vesting.
- The company plans to enter into an indemnification agreement with Mr. Smith.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, operating outlook, management commentary, contingencies, or business risks are provided. The principal disclosed item is the director appointment and related equity compensation. The filing states that Mr. Smith has no material interest in a transaction requiring disclosure under Item 404(a) of Regulation S-K and that no arrangements or understandings led to his selection.
Investor Verification Items
- Confirm the terms, exercise price, and accounting treatment of the 25,060-share director option in subsequent filings.
- Review the company’s director compensation policy and the final prospectus filed in connection with the October 26, 2020 initial public offering.
- Verify whether the planned indemnification agreement was executed and whether any future filings disclose additional governance or compensation changes.